New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2013
16:18 EDTTRGTTargacept sees FY13 revenue approximately $2.4M, consensus $2.95M
Expects its operating expenses for the year ending December 31 to be in the range of $48M-$54M and its cash, cash equivalents and investments balance at December 31 to be at least $135M. In addition, Targacept continues to expect that its current cash resources will be sufficient to meet its operating requirements at least through the end of 2015. This financial guidance includes both cash and non-cash revenue and expense items.
News For TRGT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 5, 2015
18:58 EDTTRGTStockholders of Catalyst to initially own 65% of Targacept, Catalyst combination
Subscribe for More Information
18:51 EDTTRGTTargacept, Catalyst Biosciences outline benefits of proposed merger
Subscribe for More Information
18:40 EDTTRGTTargacept to change name to Catalyst Biosciences if proposed merger closes
If the merger is consummated, Targacept’s name will be changed to Catalyst Biosciences and Targacept will apply to change its ticker symbol on the NASDAQ Global Select Market to “CBIO”. Catalyst’s CEO Nassim Usman, Ph.D., will become the President and CEO of the combined company and the other Catalyst executive officers will assume their respective positions in the combined company, with select Targacept executives remaining involved on a transitional basis.
18:36 EDTTRGTTargacept, Catalyst Biosciences enter definitive merger agreement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use